Home Blog Page 193

Trina Storage and Uzmetkombinat Explore Industrial Battery Storage Cooperation in Uzbekistan

By
Advertorial Desk
-

CHUZHOU, China, Aug. 21, 2026 /PRNewswire/ — Trina Storage, the energy storage business unit of Trinasolar, recently welcomed a delegation from Uzmetkombinat JSC to its manufacturing base in Chuzhou, China. Organized by All Solar, Trinasolar’s module distributor in Uzbekistan, the visit focused on how battery energy storage systems (BESS) could support Uzmetkombinat’s industrial energy requirements.

Trina Storage and Uzmetkombinat representatives during the delegation visit to Trinasolar’s manufacturing base in Chuzhou, China
Trina Storage and Uzmetkombinat representatives during the delegation visit to Trinasolar’s manufacturing base in Chuzhou, China

Based in Bekabad, Uzmetkombinat is an established Uzbek metallurgical producer of rolled steel, grinding steel balls, ferroalloys and other industrial products. Its delegation toured Trina Storage’s manufacturing and system integration facilities and discussed using BESS to optimize electricity loads, reduce peak demand, improve energy efficiency and strengthen power supply stability.

Trina Storage introduced its vertically integrated cell-to-system capabilities, built around in-house manufactured lithium iron phosphate cells. The platform integrates the battery management system, power conversion system, energy management system, liquid cooling and fire protection. The delegation also learned about Elementa 3, Trina Storage’s latest utility-scale BESS, which uses an in-house 587 Ah cell and provides up to 6.25 MWh of storage capacity per container. Its multilayer safety architecture includes millisecond-level early warning, UL94-5VA flammability-rated modules and composite walls providing two hours of fire resistance.

Uzmetkombinat delegation touring Trina Storage’s manufacturing and system integration facilities in Chuzhou, China
Uzmetkombinat delegation touring Trina Storage’s manufacturing and system integration facilities in Chuzhou, China

This combination of in-house technology, safety engineering and system integration is supported by Trinasolar’s inclusion in S&P Global Energy’s 2026 Tier 1 Cleantech Companies List for both photovoltaic modules and energy storage systems. Trina Storage has also secured BloombergNEF Tier 1 energy storage supplier status for ten consecutive quarters, reinforcing its international bankability and delivery credentials.

Abdullaev Bakhodir Tojimirzaevich, Chairman of the Management Board – General Director of JSC “Uzmetkombinat” said, “Uzmetkombinat is continuing to modernize its operations with a focus on energy efficiency, sustainable development and the responsible use of resources. Battery energy storage is an area we are interested in exploring as we look at ways to manage energy more effectively, strengthen operational reliability and support our longer-term decarbonization objectives.”

Following the visit, Trina Storage and Uzmetkombinat will continue discussions on the potential application of battery energy storage within Uzmetkombinat’s operations.

Ku Junheong, Vice President of Trinasolar Asia Pacific, said: “Energy-intensive industries have an important role to play in Uzbekistan’s energy transition. Battery storage can provide greater flexibility in how electricity is managed and, alongside renewable generation, support more efficient and reliable industrial energy systems. We see our engagement with Uzmetkombinat as an opportunity to apply Trina Storage’s technology and system expertise to these evolving requirements.”

This potential cooperation sits within a broader national push to provide flexible, reliable and more efficient energy solutions for Uzbekistan’s industrial sector. The discussions come as Uzbekistan accelerates energy storage deployment, with national plans calling for 4.5 GW of storage capacity by 2030.

Singapore parent develops AI oral examiner for PSLE students as AI becomes part of exam preparation

By
Advertorial Desk
-

Built by a Singapore parent, the platform uses real-time AI conversation and parent-shared prelim themes to help students practise before the PSLE oral examinations.


SINGAPORE – Media OutReach Newswire – 21 August 2026 – Articulate Intelligence has launched updated PSLE English and Chinese oral examination practice tools on its AI learning platform, giving students a way to rehearse live oral conversations at home before the national examinations.

The launch comes as AI use becomes increasingly common among primary-school-aged children. National studies found that 82.6 per cent of Singaporean children aged 10 to 13 had used AI tools. With many PSLE candidates already familiar with the technology, the more relevant question is how it supports their learning—whether it simply supplies answers or helps them think and respond independently. This distinction is particularly important in oral examinations, where students must listen, formulate their own responses, elaborate and handle follow-up questions in real time.

Articulate Intelligence’s AI Oral Examiner is designed around that real-time pressure. Students first choose English or Chinese, then select a topic from a dropdown menu. The AI examiner then speaks with the student, listens to the answer, and asks follow-up questions based on what was said. If a student freezes, the system can prompt them to expand their answer, but it does not simply hand over a model response.

Ahead of the PSLE oral examinations, the platform has also added practice topics shaped by parent-shared prelim experiences. Parents shared topics their children had encountered, which Articulate Intelligence distilled into broader themes with generated images and questions for students to practise on the platform.

The platform was created by Meng Aun Tan, Founder of Articulate Intelligence, after he struggled to help his own daughter prepare for PSLE oral examinations in 2024. He later shared an early version with parents from a school volunteer group and found that many faced the same difficulty. Today, Articulate Intelligence has close to 500 users, according to company figures, with usage rising around major examination periods.

“Oral exams are not just about knowing a good answer. Students need to think while someone is waiting, respond clearly, and keep going when they are unsure,” said Meng Aun Tan, Founder, Articulate Intelligence. “I built this first for my own children because I realised that, as a parent, I could not always give useful oral exam feedback on the spot. The AI should not replace teachers or parents, but it should give students more chances to practise, so that when they meet a real examiner, the experience feels less frightening.”

The first topic is available free for users. Other topics require paid credits or a subscription. Beyond PSLE English and Chinese oral practice, Articulate Intelligence also offers AI tools for composition grading, situational writing feedback, O-Level English oral practice, and DSA interview preparation.

Parents, schools, and tuition centres can try the platform or make enquiries at (https://articulate.com.sg).

Hashtag: #articulateintelligence #PSLE #psletraining

The issuer is solely responsible for the content of this announcement.

About Articulate Intelligence

Articulate Intelligence develops AI-powered education tools for parents, students, schools, and tuition centres. Its platform includes a real-time AI Oral Examiner for English and Chinese oral practice, as well as AI graders for composition and situational writing. Founded by Singapore parent Meng Aun Tan, the company focuses on making personalised practice more accessible while supporting, not replacing, teachers and parents. Learn more at ().

Laos Cuts 7-Day Base Interest Rate to 7% as Economic Risks Persist

By
Phoudasack Vongsay
-
A picture of Lao Kip used for illustration purpose only.

The Bank of Laos (BOL) has cut its seven-day base interest rate from 8 percent to 7 percent a year as inflation remains below the government’s 8 percent target.

The Monetary Policy Committee approved the cut at its meeting on 20 August, where it reviewed monetary policy, economic conditions, fuel prices, exchange rates and financial stability.

According to BOL, the latest decision shows continued monetary stability, with inflation remaining close to the government’s target, while the exchange rate and money supply remained within planned levels.

Inflation fell from 10.2 percent in April to 7.4 percent in June as lower fuel and transport costs and a more stable exchange rate eased pressure on consumers. But inflation edged up to 7.6 percent in July, driven mainly by surging electricity costs and continued pressure from high transport, fuel, and service prices.

Policy, Ongoing Economic Risks 

The BOL will also extend foreign exchange market operating hours by one hour, from 9 AM to 4 PM.

Despite easing inflation,the central bank warned of several risks to economic stability, including slower global growth, volatile gold and oil prices, and political uncertainty in the Middle East.

Domestic challenges also remain. High demand for foreign currency to service debt, continued use of multiple currencies and other structural weaknesses are limiting the effectiveness of monetary policy, according to the BOL.

The central bank said it will continue using a mixed monetary policy approach, including tighter foreign exchange management, centralizing government deposits, improving payment systems and coordinating with other sectors on fuel supplies, imports and economic stability.

Previous Changes

The latest decision extends a series of cuts to the BOL’s seven-day base rate over the past year.

In August 2025, the central bank cut the rate from 9.5 percent to 9 percent, followed by another reduction to 8.5 percent in November 2025 as it sought to support liquidity and credit growth amid global uncertainty, exchange-rate fluctuations and weak domestic lending.

The rate was later cut to 8 percent in 2026. The BOL kept it at that level in May before reducing it again this week.

Laos Gives Unlicensed Beauty Clinics Until November to Obtain Permits Amid Weak Oversight Concerns

By
Thongsavanh Souvannasane
-
This photo is used for representational purpose only.

The Ministry of Health has ordered unlicensed medical and beauty facilities across Laos to obtain official permits by 30 November, but the directive has raised questions over its delayed public release and how authorities will enforce the deadline.

The Ministry issued the directive on 29 May but did not publicize it until 17 August, nearly three months later.

The notice targets a broad range of unlicensed facilities, including medical and dental clinics, plastic surgery centers, beauty centers and stem cell facilities. It says many currently operate without valid medical practice licenses, fail to meet technical standards or use misleading advertising that could endanger public health.

The directive cites the Law on Medical Treatment and covers procedures including surgery, injections, liposuction, piercing, acupuncture and stem cell treatments.

Operators already providing unlicensed services must submit documents to their provincial health department or the Vientiane Capital Health Department between 1 June and 30 November. New businesses must apply through district or provincial health offices and complete the required approval process before operating.

Questions Over Enforcement

The directive has generally received a positive response from the public, with some commenters welcoming tighter regulation of the sector.

“What a great move! This regulation should have been implemented so long ago,” one commenter wrote.

But the notice leaves several questions about enforcement unanswered.

It does not specify penalties for operators that fail to obtain a license by 30 November, such as fines, equipment confiscation, closure or criminal charges. It also does not explain what action authorities will take against clinics that continue operating without licenses after the deadline.

The timing of the announcement has also drawn criticism.

“Why do you post this so late?” one commenter asked. Another wrote, “This should have been done a long time ago; it is extremely dangerous.”

The six-month registration period also raises questions about whether unlicensed clinics can continue offering higher-risk procedures while they seek approval. The directive does not say whether facilities performing surgery, injections or other potentially dangerous treatments must suspend those services during the registration period.

Nor does it clarify whether health authorities will conduct inspections while operators are applying for licenses.

The Ministry also has not said whether it will publish a list of licensed facilities, which could help patients identify clinics that have met the required standards.

The directive marks a step toward tighter oversight of Laos’ growing medical and beauty sector, but clearer information on inspections, patient protection and enforcement could determine how effectively the new requirements are put into practice.

Objective Digital Psychological Assessment Launches in Singapore, Offering Clarity for Inattention and Hyperactivity Concerns

By
Advertorial Desk
-
SINGAPORE – Media OutReach Newswire – 21 August 2026 – A new, scientifically proven digital assessment service is now available in Singapore, offering an objective window into psychological brain function for individuals struggling with inattention, hyperactivity and depression. Powered by the pioneering research of leading psychological scientists, the Digital Psychological Assessment continues to be conducted at iHealthtech NUS and is administered by www.objectiveADHDassessment.sg. The research team is translating years of cutting-edge research into a practical solution for the public.

For the first time, people in Asia can access a multimodal, objective assessment that moves beyond subjective questionnaires and interviews. The service leverages functional near-infrared spectroscopy (fNIRS), a non-invasive and painless technology that uses weak, harmless near-infrared light to measure brain activity in the frontal and temporal lobes. This is the same technology developed and validated by a team of psychological scientists whose work has been published in academic journals, including this publication and this publication, and featured in The Straits Times.

The principal investigator, who ranks among the world’s top 1–2% most highly cited psychological scientists, developed this approach to bring objective measurement to human functioning. The technology measures oxygen levels in the brain’s frontal and temporal lobes during cognitive tasks. Combined with eye-tracking and continuous performance tests, it provides a comprehensive and objective picture of inattention and hyperactivity.

This service is invaluable for parents concerned about their child’s inattention and hyperactivity, young adults, and working professionals who have long suspected neurodivergent difficulties but have lacked clear answers. By providing measurable biomarker data, the assessment helps people understand their own brain function, leading to more targeted support and interventions.

“This field often involves assessment without objective tools,” some scientists have stated, drawing a parallel to a simple test that provides a clear indication. This breakthrough offers a definitive, data-backed path towards understanding and managing one’s challenges.

The objective assessment represents a significant step forward in psychological assessment in Asia and has the potential to be extended to children and adults globally. For many, it marks the end of a long, uncertain struggle and the beginning of a clear, science-backed journey towards greater clarity and understanding.

Hashtag: #ObjectiveADHDassessment

The issuer is solely responsible for the content of this announcement.

About www.objectiveADHDassessment.sg (Singapore)

The entity is dedicated to translating research findings into real-life applications, focusing on objective, state-of-the-art psychological multimodal assessments for children and adults, leveraging technology validated by leading experts from renowned local and overseas universities.

Akeso’s AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

By
Advertorial Desk
-

HONG KONG, Aug. 21, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). The clearance allows initiation of a Phase I study in patients with advanced malignant solid tumors. Development of AK157D1 in combination with Akeso’s proprietary bispecific antibodies ivonescimab and cadonilimab is also planned.

AK157D1 is the third next-generation ADC candidate from Akeso to enter clinical development, following AK146D1 (TROP2/Nectin-4 ADC) and AK138D1 (HER3 ADC). The clearance further advances the Company’s IO2.0 + ADC2.0 strategy and expands its broad innovative oncology pipeline.

B7-H3 is highly expressed in a broad range of solid tumors, including non-small cell lung cancer, small cell lung cancer, prostate cancer, esophageal cancer, nasopharyngeal carcinoma, colorectal cancer, breast cancer, and glioblastoma, with limited expression in normal tissues. This profile supports its potential as a broad-spectrum antitumor target.

AK157D1 was developed entirely in-house and incorporates a proprietary design. In preclinical studies, it has shown potent antitumor activity together with a favorable safety profile. These attributes may help address certain limitations associated with existing ADCs, including hematologic toxicity and interstitial lung disease, and support its continued development as a potential ADC of choice in both mono or combination therapies.

Akeso is advancing its IO2.0 + ADC2.0 strategy, built on proprietary bispecific and multispecific antibody technology and centered on cornerstone IO2.0 assets including ivonescimab and cadonilimab. Through this approach, the company is elevating treatment standards for major cancers worldwide and building a broad oncology portfolio to create next-generation standard of care.

In the immuno-oncology field, Akeso has two approved bispecific antibodies for cancer treatment. The Company is actively evaluating ivonescimab and cadonilimab in combination with its proprietary next-generation ADC candidates. Increasingly, global partners recognize both ivonescimab and cadonilimab as preferred agents for combination regimens and breakthrough therapy explorations across a wide spectrum of tumor types. In the ADC space, Akeso has built a differentiated pipeline of next-generation candidates, including AK146D1 and AK138D1, which are already in clinical development, and AK157D1 and AK158D1 (a bispecific ADC), which are anticipated to enter the clinic shortly. These agents are designed to address the narrow therapeutic window and safety limitations commonly associated with first-generation ADCs.

About AK157D1

AK157D1 is a novel B7-H3-targeting ADC independently developed by Akeso. It comprises a recombinant humanized IgG1/κ monoclonal antibody site-specifically conjugated to Dxd, a camptothecin-derived topoisomerase I inhibitor, via a maleimidocaproyl-alanine-alanine-alanine (MC-AAA) linker to interchain cysteine residues. Preclinical studies have demonstrated potent antitumor activity and a favorable safety profile.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, 27 candidates have advanced into clinical trials—including 15 bispecific or multispecific antibodies and bispecific ADCs—and 8 innovative drugs have reached commercial stage.

Through efficient and groundbreaking R&D, Akeso integrates premier global resources to develop transformative medicines, deliver high-quality, affordable therapeutic antibodies to patients worldwide, and generate sustained commercial and societal value as it strives to become a global leader in biopharmaceutical innovation.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

Sarawak Wins Second M&C Asia Stella Award for Sustainability

By
Advertorial Desk
-

KUCHING, Malaysia, Aug. 21, 2026 /PRNewswire/ — Sarawak’s approach to creating lasting impact through business events has once again earned international recognition, with the destination named Best Sustainability Initiative (Destination) at the Meetings & Conventions Asia Stella Awards 2026. The win marks Sarawak’s second in the category, after 2024, reinforcing legacy impact as an important part of its approach to sustainable destination development.

Dato Sri Abdul Karim receives award, which recognises the sustainable practices of its business events industry. Award presented by Datu Hii, Jason Tan (CEO, BESarawak) and Rose Bruce (Senior Manager, Marketing & Communications, BESarawak)
Dato Sri Abdul Karim receives award, which recognises the sustainable practices of its business events industry. Award presented by Datu Hii, Jason Tan (CEO, BESarawak) and Rose Bruce (Senior Manager, Marketing & Communications, BESarawak)

The win was driven by Sarawak’s legacy impact approach, which demonstrates how business events can be intentionally designed to create meaningful long-term outcomes beyond the event itself. By focusing on economic development, social progress, and environmental responsibility, the approach connects business events with Sarawak’s Post COVID-19 Development Strategy (PCDS) 2030 and the UN Sustainable Development Goals (SDG).

This year’s recognition carries added significance as the award was determined through public nominations and voting. Public support for Sarawak reflects the growing relevance of legacy impact beyond the business events industry, showing that the value of creating meaningful, lasting outcomes is resonating with the wider community.

“Winning this award for the second time demonstrates the importance of sustainability and legacy to Sarawak’s business events strategy and wider development,” said The Honourable Dato Sri Abdul Karim Rahman Hamzah, Minister for Tourism, Creative Industry and Performing Arts Sarawak. “Sustainability must go beyond the environment to include social and economic progress, while legacy ensures that the value created through business events can continue long after an event has ended.”

Since its first M&C Asia Stella Award victory in 2024, Sarawak has continued to advance its legacy agenda through programmes and platforms focused on education, measurement and industry participation. The focus is increasingly on embedding legacy throughout the event journey and strengthening the industry’s ability to translate intent into meaningful outcomes.

“This recognition reflects the collective effort behind Sarawak’s legacy journey,” said Datu Hii Chang Kee, Deputy State Secretary (Operation) and Chairman of BESarawak. “What began with advocacy is gaining greater participation across the industry. Legacy is ultimately about shaping the future together, with government, industry, organisers and communities each playing a role in creating shared and meaningful outcomes.”

“This award signals that legacy impact is gaining greater relevance, not only for Sarawak but across the Asia Pacific business events industry,” said Jason Tan Chin Foo, Chief Executive Officer of BESarawak. “Our next phase is to drive greater adoption across the ecosystem, ensuring that legacy outcomes are consistently planned, measured and demonstrated, while strengthening the industry’s capability to deliver them. That is how we turn recognition into lasting value for Sarawak.”

The M&C Asia Best Sustainability Initiative (Destination) Award 2026 marks another milestone in Sarawak’s legacy journey, strengthening its commitment to advancing legacy impact as a driver of sustainable destination development.  

– END –

About Business Events Sarawak (BESarawak) / Biro Konvensyen Sarawak / 砂拉越会展局
Established by the Sarawak Government in 2006, Business Events Sarawak (BESarawak) is the destination marketing organisation responsible for attracting high-value business events aligned with the Post COVID-19 Development Strategy 2030. Through business events, BESarawak drives visitor expenditure, innovation, global expertise, and strategic partnerships – creating economic, social, and environmental impact that strengthens Sarawak’s economy, intellectual capital and sustainability. More at www.businesseventssarawak.com.

About Legacy Impact
Legacy impact refers to the positive, long-term change generated through business events. In Sarawak, conventions and exhibitions are structured to create legacies, whereas corporate meetings and incentive programmes emphasise the experience of legacies. Through strategic event planning, programming, and curated experiences, Sarawak aims to build a legacy of innovation, collaboration, and sustainable impact, generating tangible benefits for communities, industries, and the region.

Institutional-Grade Allocation in a Single Account: BiFu’s Wealth Suite Takes Shape, Bringing Managed Funds and RWA Under One Roof

By
Advertorial Desk
-

HONG KONG, Aug. 21, 2026 /PRNewswire/ — BiFu, an all-asset trading platform, has completed the build-out of its Wealth suite, which runs on two product lines: a Wealth product line offering five funds managed by licensed asset management institutions across fixed income, gold, quantitative strategies, Hong Kong IPOs, and foreign exchange; and an RWA (real-world assets) product line that brings tokenized private-market equity on-chain, opening a category once reserved for institutions and high-net-worth investors.

These are not two separate features. They answer the same question: once a user’s capital crosses a certain threshold, what else can an exchange offer?


The Industry Backdrop: RWA Is Now a $38 Billion Market

According to industry data platform RWA.xyz, as of August 2026, total on-chain RWA value stands at roughly $38 billion, total asset holders have surpassed 2 million, up more than 60% in 30 days, and asset issuers number 281.

Two numbers deserve a closer look. First, holder growth is far outpacing growth in total value: new inflows are dominated by smaller tickets, and RWA is moving from an institutional niche toward retail adoption. Second, 281 issuers against two million holders means supply remains scarce, which helps explain why leading offerings fill their subscription windows quickly.

The asset mix, however, is a reminder that RWA is not shorthand for “low risk.” US Treasuries, at roughly $14.7 billion, are a conservative core holding; but commodities, private credit, equities, private equity, and alternative funds sit closer to the medium-to-high end of the risk spectrum.

BiFu’s read: Treasuries and commodities solve a yield problem, but the real growth frontier lies in private equity and alternative funds, because those solve an access problem. What retail investors lack is not an extra point of yield. It is access to assets they simply cannot buy.

The Wealth Line: Five Funds, Five Distinct Sources of Return

BiFu’s Wealth product line currently hosts five funds, all rated Medium Risk, whose underlying assets do not overlap: a compact allocation shelf rather than a product list.

FX Stable Return Fund: expected annualized rate of return of 8.00% to 10.00%, a 365-day offering cycle, initial investment of 10,000 USDT, and a subscription quota of 5,000,000 USDT. The fund invests in a master fund established by Trivesta Group in the Cayman Islands, managed through foreign exchange (FX) and precious metals (including gold) trading strategies within an established risk management framework focused on controlling volatility and drawdowns.

Gold Spot Enhanced Fund: It adopts a classic strategy of “gold spot base holdings + dynamic option yield enhancement (e.g., covered calls)”, capturing gold’s long-term appreciation Beta through spot positions while earning option premium Alpha during market consolidation. Managed by Duxton Asset Management.

Ark One Quantitative Fund: expected annualized rate of return of 15.00%, a 365-day cycle, initial investment of 20,000 USDT, a quota of 5,000,000 USDT, and recruitment progress of 69.85%. The only fund with digital assets as the underlying, it is an arbitrage yield-enhanced quantitative fund of funds combining “steady arbitrage + flexible timing enhancement” to navigate bull and bear cycles. Primary manager Wellspring Asset Management holds a BVI Approved Manager license, with over 7 years of crypto quantitative experience and historical AUM exceeding USD 140 million; Shenwan Hongyuan Securities (Singapore) acts as co-manager.

Stable Yield Fixed Income Fund: expected annualized rate of return of 7.00%, a 180-day cycle, initial investment of 5,000 USDT, a quota of 5,000,000 USDT, and recruitment progress of 75.39%. The only six-month product, it adopts the MAS-regulated VCC structure and invests in supply chain finance assets with a real trade background, targeting counter-cyclical industries such as packaging, plastics, and deep processing of agricultural products. Duxton Asset Management is primary manager, with Shenwan Hongyuan Securities (Singapore) as co-manager.

HKEX Anchor Investment Flagship Fund: expected annualized rate of return of 15.00%, a 365-day cycle, initial investment of 10,000 USDT, a quota of 5,000,000 USDT, and recruitment progress of 56.92%. Managed by Duxton Asset Management, it directly participates in the offline anchor placement of high-quality unicorn IPOs on the Hong Kong Exchanges and Clearing (HKEX), capturing initial offering dividends while avoiding long-term secondary market volatility.

The shelf has a clear layered design: fixed income, FX, Hong Kong IPOs, gold, and crypto quant each contribute a distinct return stream, with entry points tiered from 1,000 to 20,000 USDT.

All product information is drawn from BiFu’s public website and does not constitute investment advice or any promise of returns. Expected annualized rates are projections, not guarantees; past performance is not indicative of future results, and investments involve the risk of principal loss.

The Manager Lineup: A Licensed Roster Rarely Seen in Crypto Wealth Products

Duxton Asset Management, founded in 2009, is dually regulated by the Monetary Authority of Singapore (MAS, holding a CMS license) and Australia’s ASIC. Its core team originated from the Asset Management division of Deutsche Bank, with 17 years in cross-border investment and wealth management. Shenwan Hongyuan Securities (Singapore) is a holding subsidiary of a large comprehensive securities firm directly under China Investment Corporation (CIC) and Central Huijin. Wellspring Asset Management holds a BVI Approved Manager license and specializes in digital asset quantitative hedging. Trivesta Group covers the FX and precious metals mandate and issues two equity projects on the RWA line.

Under BiFu’s roadmap, the Wealth suite will operate as an open venue: the platform provides the compliance rails, user base, and settlement infrastructure, and invites additional licensed asset managers to issue products and assets.

The RWA Line: Turning Private-Market Tickets into Stablecoin-Sized Shares

BiFu’s RWA Project List currently features three investable projects, all structured as funds and rated Medium Risk:

StepFun Equity Project: initial investment of $15,000, issued by Trivesta Group, scale upper limit of $5,000,000, recruitment progress 56.91%. It invests in the Pre-IPO equity of StepFun, a leading unicorn in China’s Artificial General Intelligence (AGI) sector, standing in the domestic first tier for multi-modal large model technology.

Sunrise Equity Project: initial investment of $20,000, also issued by Trivesta Group, scale upper limit of $5,000,000, recruitment progress 41.65%. It invests in Sunrise, a scarce target in China’s AI computing infrastructure sector focused on the independent R&D of dedicated GPUs for large model inference.

Musk Unicorn Opportunities Fund: initial investment of $50,000, managed by Duxton Asset Management, scale upper limit of $10,000,000, now marked Fundraising Closed. A Pre-IPO unicorn opportunities fund holds scarce equity of pre-listing tech giants through a compliant fund structure.

All three are private-market equity that ordinary investors can barely reach through traditional channels. This is where RWA delivers its most tangible value: allocations that once started at a million dollars compress to $15,000 to $50,000, subscribable in stablecoins. It converts what people could not buy into products they can hold by the share. Private-market equity remains medium-to-high risk, and expected annualization figures do not constitute any guarantee of returns.

For Asset Issuers: BiFu’s Next Phase

RWA is a two-sided market. BiFu has laid out the path it will offer asset issuers going forward, in three steps: asset tokenization, market trading, and investment allocation. Projects move from application through compliance structuring to token issuance; tokens then list, connect to liquidity, and open to global investors, who allocate in stablecoins and can exit through the secondary market. 

BiFu’s support spans compliance architecture, smart contracts, and full-cycle issuance services, underpinned by partner law firms, auditors, and custodians. For asset owners, fundraising and liquidity get solved together: a tokenized issuance creates a continuously tradable market the moment the raise completes.

The Second Half for Exchanges Is a Contest of Asset Supply

As the industry settles into a battle for existing users, pure trading-efficiency gains yield less and less. BiFu’s Wealth suite points to a different path: the core competency of an exchange is shifting from matching trades to organizing assets. Whoever can source assets others cannot, and package institutional-grade structures into retail-accessible shares, will keep the users with the largest balances.

Users still need only one account. What that account can hold is expanding from crypto to gold, foreign exchange, supply chain finance, Hong Kong IPOs, and private-market equity.

About BiFu

BiFu is a next-generation all-asset trading platform connecting trading, assets, and future markets. Through a unified account system, BiFu offers crypto derivatives, FX CFDs, tokenized stocks and RWA, prediction markets, Earn, and copy trading.

One Account, Trade the World.

1...192193194...6,631Page 193 of 6,631